3 + 7 + FLT3 inhibitors: 1 + 1 ≠ 2

In this issue of Blood, Knapper et al analyzed 2 consecutive randomized Medical Research Council (MRC) trials in newly diagnosed patients with mutant FMS-like tyrosine kinase-3 (FLT3) acute myeloid leukemia (AML) and suggested no benefit for the addition of the kinase inhibitor lestaurtinib to chemotherapy.1